Latest Earnings Results: Q3 '26
Estimated EPS
-$0.33
Reported EPS
-$0.30
Surprise
+8.83%
Estimated Rev
$4.51M
Reported Rev
$13.16M
Surprise
+191.6%
• Reported GAAP EPS of -$0.30 up 6.25% YoY • Reported revenue of $13.16M up 72.93% YoY • Wave Life Sciences expects current cash, cash equivalents, and marketable securities to fund operations into 3Q 2028; a $12M GSK milestone is expected in 4Q 2026 and is excluded from runway.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.32 | -- | -- | N/A |
Q3 '26 | -$0.33 | -$0.30 | 8.83% | BEAT |
Q2 '26 | -$0.30 | -$0.34 | -12.41% | MISSED |
Q1 '26 | -$0.32 | -$0.13 | 59.82% | BEAT |
Q4 '25 | -$0.27 | -$0.30 | -9.56% | MISSED |